蒂尔泽帕提德在2型糖尿病中的安全性:使用FDA FAERS数据库对不良事件的不成比例分析
Endocrine connections
|July 9, 2025
概括
蒂尔泽帕提德是一种双GIP/GLP-1受体激动剂,在现实数据中显示出常见的胃肠道事件和注射部位反应. 新的安全信号,如上呼吸道感染,需要谨慎监测,特别是在治疗的早期.
科学领域:
- 药监和药物安全 药监和药物安全
- 内分泌学和新陈代谢学
背景情况:
- 蒂尔泽帕提德是一种双重的依赖葡萄糖的胰岛素型多 (GIP) 和类似葡萄糖-1 (GLP-1) 受体激动剂.
- 已批准的适应症包括2型糖尿病和肥胖管理.
- 现实世界的安全数据对于超越临床试验的全面理解至关重要.
研究的目的:
- 通过使用现实世界的数据来评估与tirezepatide相关的不良事件.
- 识别潜在的新安全信号并确认已知的风险.
- 分析不良事件的发病时间,特别是在不同年龄组.
主要方法:
- 利用了来自FDA不良事件报告系统 (FAERS) 的数据.
- 在2022年5月至2024年第四季度的报告中使用了四种算法进行不成比例分析.
- 需要在所有四种方法和至少三个信号确认案例中达成共识.
主要成果:
- 从20,350份报告中确定了105个重大不良事件.
- 已确认的已知风险包括胰腺炎和低血糖症;常见事件包括胃肠道疾病和注射部位反应.
- 检测到新的信号,如上呼吸道感染和绝经后出血;在老年人中观察到较早的发病.
结论:
- 现实世界的数据分析与已知的tirezepatide胃肠道和胰腺风险一致.
- 潜在的新安全问题,包括感染和出血,需要进一步调查.
- 警监测是必不可少的,特别是在初始治疗阶段和老年患者.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
269
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
269
Oral Hypoglycemic Agents: Biguanides and Glitazones
309
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
309
Pharmacovigilance
999
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
999
Insulin: Dosing Regimen and Adverse Effects
265
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
265
Glucagon-like Receptor Agonists
431
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
431
Drug Regulation
1.9K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.9K


